로딩 중…
지수 로딩 중…
Nurix Therapeutics, Inc.
NRIX· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$23.22+0.04%
2026-08-03
Financials
Valuation Metrics
Nurix Therapeutics, Inc.'s Market Cap is $2.40B. At end of 2025 it was $2.09B. Ranked #1928 of 3,112 in US market (top 62%), #717 of 1,445 on NASDAQ (top 50%), #117 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 43%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.40B | US#1,928/3,112 Sec#117/269 |
| Revenue | $37M | US#2,881/3,112 Sec#163/269 |
| Net Income | $-341M | US—/3,112 Sec—/269 |
| Total Assets | $536M | US#2,714/3,112 Sec#144/269 |
| Net Assets | $403M | US#2,402/3,112 Sec#131/269 |
| Value | ||
| P/B | 5.96x | US#2,307/3,112 Sec#156/269 |
| P/S | 65.31x | US#2,891/3,112 Sec#172/269 |
| FCF Yield | -12.68% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -84.78% | US#2,832/3,112 Sec#212/269 |
| ROA | -63.74% | US#3,012/3,112 Sec#243/269 |
| Op. Margin | -982.37% | US#2,919/3,112 Sec#177/269 |
| Revenue Growth | -79.47% | US#2,918/3,112 Sec#174/269 |
| Financial Health | ||
| Debt Ratio | 33.01% | US#367/3,112 Sec#111/269 |
| Total Debt | $58M | US#2,511/3,112 Sec#143/269 |
| FCF | $-305M | US#2,788/3,112 Sec#241/269 |
| Cash | $68M | US#2,437/3,112 Sec#205/269 |
| Current Ratio | 6.34x | US#377/3,112 Sec#123/269 |
| Performance | ||
| 1Y Return | 110.33% | US#280/3,112 Sec#77/269 |
| 1M Return | -3.13% | US#2,036/3,112 Sec#104/269 |
| From 52W High | -7.45% | US#805/3,112 Sec#35/269 |
| 1Y MDD | -37.48% | US#1,830/3,112 Sec#132/269 |
| Trading | ||
| Volume | 1,272,316 shares | US#1,274/3,112 Sec#124/269 |
| Trading Value | $29M | US#1,743/3,112 Sec#120/269 |
| Per Share | ||
| EPS | $-2.78 | US—/3,112 Sec—/269 |
| BPS | $5.67 | US#2,160/3,112 Sec#120/269 |